VSA003

DRUG2 trials

Sponsors

Visirna Therapeutics HK Limited

Conditions

DyslipidemiasFamilial HypercholesterolemiaHomozygous Familial Hypercholesterolemia (HoFH)Hypertriglyceridemia

Phase 1

A VSA003 Phase 1 Study in Chinese Adult Healthy Volunteers

CompletedNCT05851066

Visirna Therapeutics HK LimitedDyslipidemias, Familial Hypercholesterolemia, Hypertriglyceridemia

Start: 2023-06-01End: 2024-05-07Updated: 2025-09-12

Phase 3

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients

Active, not recruitingNCT06712771

Visirna Therapeutics HK LimitedHomozygous Familial Hypercholesterolemia (HoFH)

Start: 2024-11-27End: 2027-12-30Updated: 2026-05-05